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Abstract:  Objectives:  The  aims  of  this  study  were  to  evaluate  adherence  of  patients  and  medical  staff  to  warfarin 
guidelines and assess clinical outcome and predictors of treatment failure. 
Methods:  This  cross-sectional  survey  involved  out-  and  in-patient  subjects  receiving  warfarin.  Patient  attentiveness, 
compliance, co-morbidities, complications, and international normalized ratio (INR) as well as adherence of medical staff 
to established warfarin treatment guidelines were recorded. 
Results: One-hundred-sixty patients were recruited (mean ± SD age = 54 ± 1.3 years; 46% males; 77% overweight/obese). 
Indications for warfarin were atrial fibrillation (35%), deep vein thrombosis (28%), prosthetic heart valve (20%) and 
stroke or dilated cardiomyopathy (12%). “Warfarin booklets” were made available to 25% of the patients, and ~80% of 
the recipients reported inadequate understanding of its content. INR was strictly monitored in 23% of the patients; ~70% 
never  received Information Leaflets;  ~88% were unaware of warning labels;  and ~58% were unaware  that over-the-
counter medications may affect warfarin. Therapeutic INR (2.9 ± 0.2; 76 days) was achieved in 73%; 20% had high INR 
(3.7 ± 0.1; 18.6 days) and 7% had low INR (1.6 ± 0.1; 16.7 days). Of the patients with high INR, 2.5% had major bleeding 
events.  Of  the  patients  with  low  INR,  5%  had  thromboembolic  events.  Poor  compliance  and  co-morbidities  were 
associated with adverse events (p=0.01). 
Conclusions: Attentiveness and adherence to warfarin treatment and monitoring guidelines are suboptimal among patients 
and  medical  staff.  Novel  strategies  are  necessary  to  alert  patients,  pharmacists  and  physicians  on  the  seriousness  of 
warfarin treatment failure. 
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INTRODUCTION 
  Warfarin  is  a  commonly  used  anticoagulant,  which 
reduces the occurrence of thromboembolic events (TEE) [1]. 
The  drug,  however,  is  among  the  top  10  agents  linked  to 
serious side  effects [2].
 It is labeled as  a “medication that 
poses high risks to patients and requires safety controls” [3]. 
Consistently,  bleeding  and  TEE  complications  linked  to 
warfarin are relatively common emergency events [2]. 
  Several  consensus  guidelines  have  been  developed  to 
enhance  medical  knowledge  and  competency  prior  to 
initiating  warfarin  treatment  [4].  Numerous  audits 
worldwide,  however,  revealed  fundamental  deficiencies  in 
many aspects of warfarin therapy [5]. Furthermore, patients 
on  long-term  warfarin  experience  sharp  fluctuations  in 
international normalized ratio (INR) due to varying diets, co-
medications,  compliance  and  alcohol  consumption.  Thus, 
strict laboratory monitoring is essential [6]. 
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  The  primary  aim  of  this  study  was  to  prospectively 
monitor  adherence  of  patients  and  medical  staff  (nurses, 
pharmacists  and  physicians)  to  the  established  warfarin 
therapy  guidelines.  The  secondary  aim  was  to  assess  the 
impact of current warfarin practice on patient outcome. 
MATERIAL AND METHODS 
  This  prospective  observational  cross-sectional  warfarin 
study  was  conducted  in  the  out-  and  inpatient  facilities  
of  Al  Ain  Hospital  (Al  Ain,  United  Arab  Emirates)  from 
December  2009  to  December  2010.  The  study  was  
approved  by  Al  Ain  Medical  District  Human  Research 
Ethics Committee. Informed consent was obtained for each 
patient.  
PATIENTS 
  One-hundred-sixty  patients  on  warfarin  were  recruited. 
Patients  were  randomly  selected  from  the  Cerner  data- 
base (800 new patients on warfarin  every year)  at Al-Ain 
Hospital. The inclusion criteria were warfarin therapy for >3 
months,  intent-to-treat  for  >12  months,  and  ability  to 
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DATA COLLECTION 
  A 10-item “warfarin audit questionnaire” was developed 
and  validated  by  the  Drug  Utilization and  Evaluation 
Subcommittee  (DUES) at  Al  Ain  Hospital.  The  survey  
was  further  validated  for  content  (reliability  correlation 
coefficient  =  0.76)  by  5  physicians  and  2  clinical 
pharmacists. It was then translated from English to Arabic 
and  vice  versa  to  avoid  systematic  bias  and  to  ensure 
uniformity of approach. The Arabic version was used when a 
patient was unable to understand English.  
  The  questionnaire  was  administered  by  trained 
pharmacists  and  nurses.  The  items  included  perception  of 
warfarin,  knowledge  on  warfarin  clinical  use,  warfarin 
regimen,  compliance,  INR  profile,  indication  for  warfarin 
use, bleeding history, possession of  the  Yellow/  Blue oral 
anticoagulation therapy booklet, comprehending the booklet 
content, need to show the booklet when collecting warfarin, 
concurrent  diseases,  co-medications  (including  over-the-
counter drugs, prescriptions, vitamins, dietary supplements 
and  traditional  medicine),  and  dietary  vitamin  K  intake. 
Patients were also asked about the advice on dose changes, 
INR results, provision of Patient Information Leaflet, warfarin 
label  (e.g.,  stating  “warfarin  must  be  taken  in  accordance 
with  their  latest  INR  blood  test”)  and  complications  (e.g., 
bleeding and TEE).  
ANALYSIS 
  Associations between warfarin dose, age, gender, body-
mass-index,  indications, co-morbid conditions and targeted 
INR  were  evaluated  by  Pearson  correlation  test  and 
significance  by  analysis  of  variance  (ANOVA).  Linear 
regression analysis was used to model relationships of INR 
target  with  other  variables.  Variables  from  univariate 
statistical  tests  were  entered  into  multiple  stepwise 
regression  analysis.  Statistical  analyses  were  performed 
using  SPSS  for  Windows,  version  18.0  software  (SPSS, 
Chicago,  IL).  A  significant  difference  (two-tailed)  was 
defined as p< 0.05.  
RESULTS 
Patient Characteristics 
  Patient age (mean ± SD) was 54 ± 1.3 year, 46% were 
males  and  77%  were  overweight/obese  (BMI  >30  kg/m
2). 
Warfarin was given for atrial fibrillation (35%), deep vein 
thrombosis (28%), prosthetic heart valve (20%), and stroke 
or  dilated  cardiomyopathy  (12%),  Table  1.  None  of  the 
patients  reported  a  use  of  aspirin,
  non-steroidal  anti-
inflammatory drugs, high-dose penicillin or moxolactam (all 
known to increase the risk of warfarin-associated bleeding) 
[7].  
INTERVIEW QUESTIONNAIRE 
  Warfarin booklets were made available to only 25% of 
the patients, and ~80% of the recipients reported inadequate 
understanding  of  its  content.  Similarly,  ~80%  were  never 
asked to show their booklet when collecting warfarin. INR 
was  strictly  monitored  in  only  23%  of  the  patients. 
Moreover,  ~70%  never  received  Patient  Information 
Leaflets; ~88% were unaware of warning labels indicating 
“warfarin must be taken in accordance with the latest INR 
result”;  and  ~58%  were  unaware  that  over-the-counter 
medications may affect warfarin therapy (Table 2). 
INR 
  Sustained therapeutic INR (mean ± SD; 2.9 ± 0.2) was 
documented  in  73%  of  the  patients  (duration  =  76.1  ±  2 
days). High INR (3.7 ± 0.09) was noted in 20% of the patient 
(duration = 18.6 ± 3 days) and low INR (1.6 ± 0.12) in 7% 
(duration  =  16.7  ±  2  days).  Patients  received  advices  to 
change warfarin dosing by physicians (61%), nurses (23%) 
and pharmacists (16%). 
Table 1.  Patient Characteristics (n = 160) 
Parameters  Frequency (%)  Mean INR  p 
Age Group (Years) 
 17 to 39  35 (21.9)  2.7 
 40 to 59   68 (42.5)  2.7 
 60 to 79  47 (29.4)  2.6 
 > 80  10 (6.2)  2.8 
0.001 
Gender 
 Male   73 (45.6)  2.7 
 Female  87 (54.4)  2.8 
insignificant 
Nationality 
 Arabs  63 (39.4)  2.5 
 Emiratis  47 (29.4)  2.4 
 Asians   35 (21.8)  2.6 
 Others  15 (9.4)  2.5 
insignificant 
Marital status 
 Married  131 (81.9)  2.6 
 Unmarried  29 (18.1)  2.7 
insignificant 
BMI (kg/m
2) 
 ≤ 25  37 (23.1)  2.5 
 > 25 to < 30  51 (31.9)  2.4 
 > 30  72 (45.0)  2.6 
insignificant 
Indications 
 Atrial fibrillation  56 (35.0)  2.7 
 Deep vein thrombosis  45 (28.1)  2.6 
 Prosthetic heart valve  32 (20.0)  3.1 
Stroke and 
cardiomyopathy 
20 (12.5)  2.4 
 Pulmonary embolism  7 (4.4)  2.8 
0.002 
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COMPLICATIONS 
  Emergency visits or hospitalizations occurred in 22% of 
the patients, mainly for TEE (5%, INR =1.6 ± 0.12), major 
bleeding (2.5%, INR = 3.7 ± 0.09), minor bleeding (5.2%, 
INR  =  3.3±  0.17)  and  unrelated  causes  (9.3%).  Abnormal 
bleeding  was  reported  frequently  (all  with  high  INR), 
including  hematemesis  (25.3%,  INR  =  3.8  ±  0.06),  cuts 
associated  with  shaving  (21.8%,  INR  =  3.4  ±  0.07),  gum 
bleeding  (19.9%,  INR  =  3.6  ±  0.04),  wound  bleeding 
(14.6%, INR  = 3.7 ± 0.04), melena (11.3%, INR =3. 4  ± 
0.09) and other bleeding sites (7.1%, INR = 3.6 ± 0.09). 
PREDICTORS 
  Multivariate  analyses  revealed  younger  age,  lower 
warfarin  dosing,  less  co-  morbid  conditions,  and  better 
compliance  were  independent  predictors  of  achieving  a 
sustained therapeutic INR (Table 3). 
DISCUSSION 
  The  primary  objective  of  this  study  was  to  assess  
the  quality  of  care  for  patients  receiving  hospital-initiated 
(in-  and  out-patient)  warfarin  therapy.  The  secondary 
objective included assessing patient attentiveness to critical 
information on the use of warfarin. The study also examined 
whether  our  tertiary-care  hospital  effectively  implemented 
the  warfarin  therapy  guidelines.  These  guidelines  were 
established  to  assure  patients  continuously  receiving 
appropriate warfarin dosing based on INR and other criteria, 
such as specific indications for warfarin and assessment of 
associated risk factors [8]. The guidelines emphasized that 
patients on warfarin should have detailed records of relevant 
clinical  information  and  INR  values  in  a  booklet. 
Unfortunately, such data were missing for  the  majority of 
patients. 
  Only 25% of the patients had warfarin therapy booklets, 
and  most  of  the  recipients  admitted  inadequate 
understanding  of  its  content.  This  finding  suggests  that 
medical  staff  who  prescribed  warfarin  did  not  thoroughly 
explain  necessary  facts  to  patients.  Consistently,  most 
patients  were  never  asked  to  show  their  booklets,  had  no 
discussion  pertinent  to  the  booklet  content,  and  did  not 
comprehend the importance of regular INR measurements. 
Over 50% of the patients were unaware that certain over-the-
counter medications may adversely affect warfarin therapy. 
  Thus, the data clearly show healthcare providers do not 
strictly  adhere  to  the  recommended  warfarin  therapy 
guidelines. This observation could, in part, reflect dependency 
of many physicians on electronic records to check INR and 
adjust dosing with minimum patient contact. 
  Regarding therapeutic INR, the results show that 27% of 
the patients never attained acceptable target levels. Of note, 
sustained therapeutic INR was obtained in 76% of the days. 
Table 2.  Interview Questionnaires 
Patient’s Response 
Yes  No 
Question Statements  N (%)  N (%) 
1) Do you currently have a copy of the Yellow/ Blue Oral Anticoagulation Therapy (warfarin) Booklet?  40 (25.0)  120 (75.0) 
2) If you have the booklet, do you fully understand its contents?  31 (19.4)  129 (79.6) 
3) Were you asked to show your booklet when you collected your warfarin?  33 (20.6)  127 (79.4) 
4) Are you having regular INR to ensure the dose is appropriate?  123 (76.9)  37 (23.1) 
6) When warfarin is issued, do you always receive a Patient Information Leaflet?  47 (29.4)  113 (70.6) 
7) When warfarin is issued, is there always a label stating: “it must be taken in accordance with your latest INR test”?  20 (12.5)  140 (87.5) 
8) Are you aware that some medications, which can be purchased over the counter without prescription, may also 
affect your warfarin? 
68 (42.5)  92 (57.5) 
The INR; international normalization ratio, level was explained to the patients. 
 
Table 3.  Significant  Predictors  of  “Achieving  Sustained  Therapeutic  International  Normalized  Ratio  (INR)”  on  Multivariate 
Analyses 
Variable Entered (Step-wise)  Confidence Interval  Odds Ratio  p 
Age  - 2.3 to - 0.34  - 1.47  0.015 
Indication for warfarin   - 4.5 to - 1.3  - 2.46  0.018 
Warfarin dose  - 4.3 to - 1.8  - 3.12  0.021 
Co-morbid status  - 2.1 to - 0.57  - 1.67  0.042 
Compliance   - 3.9 to - 1.46  - 2.63  0.037 
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INR  in  the  remaining  days  was  either  high  or  low, 
predisposing  to  bleeding  or  thrombosis,  respectively.  This 
finding is consistent with other reports showing difficulty in 
maintaining therapeutic INR >70% of the days [5]. Similar 
to another study, ~5% of the patients developed TEE [9].
 The 
bleeding  episodes,  on  the  other  hand,  were  much  more 
frequent  then  found  in  other  studies  [10],  which  raised  a 
major concern about the safety of warfarin. 
CONCLUSIONS 
  Adherence  to  warfarin  treatment  and  monitoring 
guidelines is crucial. Patients’ attentiveness was found to be 
limited. Novel programs, such as teaching films and group 
discussions  can  be  used  as  vehicles  to  deliver  useful 
information. Prescribing warfarin should be strictly coupled 
to adequate patient education. 
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